PAVmed Provides Business Update and Second Quarter 2024 Financial Results

Go back to PAVmed Provides Business Update and Second Quarter 2024 Financial Results

Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings

August 13, 2024 2:57 PM EDT

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).

The analyst comments "We reiterate our Overweight rating and 12-month price target of $3.00 on Lucid Diagnostics' (LUCD) shares following the company reporting 2Q24 operating results and providing... More